Parvovirus formulation for treating tumors

US11324788B2 · kind B2 · utility

Assignees

• Deutsches Krebsforschungszentrum · DE
• RUPRECHT - KARLS - UNIVERSITÄT HEIDELBERG · DE

Inventors

• Barbara Leuchs · Heidelberg, DE
• Karsten Geletneky · Heidelberg, DE
• Jean Rommelaere · Heidelberg, DE
• Christiane Dinsart · Ladenburg, DE
• Michael Dahm · Munich, DE
• Ottheinz Krebs · Hersbruck, DE

Key dates

• Filing date: Mar 20, 2020
• Grant date: May 10, 2022
• Expiry date: Mar 20, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described is a parvovirus formulation which comprises (a) at least 1×109 pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus such as LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus or Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl2×2 H2O, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium. A preferred use is the therapy of a brain tumour by intratumoral injection.